Marjan M Naeini, Felicity Newell, Lauren G Aoude, Vanessa F Bonazzi, Kalpana Patel, Guy Lampe, Lambros T Koufariotis, Vanessa Lakis, Venkateswar Addala, Olga Kondrashova, Rebecca L Johnston, Sowmya Sharma, Sandra Brosda, Oliver Holmes, Conrad Leonard, Scott Wood, Qinying Xu, Janine Thomas, Euan Walpole, G Tao Mai, Stephen P Ackland, Jarad Martin, Matthew Burge, Robert Finch, Christos S Karapetis, Jenny Shannon, Louise Nott, Robert Bohmer, Kate Wilson, Elizabeth Barnes, John R Zalcberg, B Mark Smithers, John Simes, Timothy Price, Val Gebski, Katia Nones, David I Watson, John V Pearson, Andrew P Barbour, Nicola Waddell
Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and methylation data from 115 oesophageal adenocarcinoma patients mostly from the DOCTOR phase II clinical trial (Australian New Zealand Clinical Trials Registry-ACTRN12609000665235), with exploratory analysis pre-specified in the study protocol of the trial. We report genomic features associated with poorer overall survival, such as the APOBEC mutational and RS3-like rearrangement signatures...
May 31, 2023: Nature Communications